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Abstract
The COVID-19 pandemic has revealed the need of novel diagnostic technologies for rapid and
accurate virus detection. In the European CONVAT project, a point-of-care nanophotonic
biosensor is being developed for the direct, fast and specific identification of severe acute
respiratory syndrome coronavirus 2 from both human patient samples and animal reservoirs. The
technology will provide a quantitative detection of the viral load and it can be implemented in
decentralized settings to improve the early diagnosis and clinical management of patients as well as
coronavirus environmental monitoring to prevent future outbreaks.
1. Introduction
In December 2019, a new coronavirus was identified as the cause of a disease outbreak (COVID-19)
originated in Wuhan, China. The virus, known as the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), cause an upper respiratory tract infection with common mild symptoms like cough, fever
and breathing difficulties for the majority of the infected people, but it can also trigger inflammatory
complications (e.g. pneumonia, multiple organ dysfunction syndrome), requiring intensive care assistance
and, unfortunately, leading to patient’s death. In March 2020, the World Health Organization (WHO)
declared the COVID-19 outbreak a pandemic and, to date (October 2020), it has infected more than
44.5 million people globally, with more than 1 million deaths [1, 2].
Given the health and social emergency with the dramatic spread of COVID-19 pandemic, rapid, accurate,
and sensitive diagnostic techniques to promptly provide an accurate virus detection are required to enable an
early infection identification, to improve patient management, and to stop and control the disease
transmission. In fact, reliable and early diagnosis of COVID-19 has become one of the major challenges in
the correct management of the pandemic. Current diagnostic techniques mainly rely on polymerase chain
reaction (PCR) tests [3, 4]. PCR assays consist in detecting and identifying the specific genomic material
(RNA) of the virus via enzyme-mediated amplification of targeted genes. Most of the approved COVID-19
PCR kits target specific sequences like RdRp, E, N or ORF1ab genes, corresponding to highly conserved
regions of the virus genome. PCR tests provide the required sensitivity and specificity together with clinical
robustness, but the relatively long time to result (between 2 and 6 h) and the need of samples transport to
specialized laboratories, delays overly the diagnosis results and hampers the massive population screening
[5]. New PCR-related modalities have been proposed, such as the loop-mediated isothermal amplification or
the rolling circle amplification, as well as emerging CRISPR-based techniques seeking for a point-of-care
(POC) genomic assay, although their rapid implementation in clinics is still complex [6–8]. Rapid antigen
diagnostic tests based on lateral flow assays (LFAs) are a good alternative, offering fast detection (15 min
approximately). These immunochromatography strips detect viral antigens, mostly the N protein, via a
sandwich assay. However, they usually present low sensitivity and reliability, especially when the viral load is
low [9, 10]. Additionally, serological assays are also being used as complementary diagnosis technique, either
with conventional techniques (chemiluminiscence or enzyme-based immunosorbent assay) or in the LFA
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format. This blood-based analysis detects the human antibodies generated upon infection, therefore they
cannot be employed as early diagnostics but rather as retrospective and confirmatory approach.
Strong worldwide efforts are pursued to surpass this bottleneck by developing reliable, fast and
user-friendly diagnostics tests than can be employed at the point-of-need [9, 11]. Biosensor technology is
one of the most well prepared to tackle this challenging goal. Biosensors are integrated systems that
combine specific biorecognition agents (e.g. antibodies, enzymes, or DNA strands) with a transducer
(i.e. electrochemical, optical, or mechanic) in such a way that when the targeted analyte interacts with the
bioreceptor, a series of physicochemical changes produced on the transducer can be translated into readable
and measurable signals for quantitative analysis. Several biosensor platforms have been produced in the last
decades for virus analysis, demonstrating highly sensitive and selective detection in a few minutes directly
from clinical samples [12–14]. Among them, photonic biosensor technologies have gained significant
attention, owing to their versatility, label-free monitoring, and outstanding sensitivity. Moreover, photonic
biosensors present capabilities to be multiplexed and miniaturized, meeting the requirements of POC testing
[15]. Thereby, label-free nanophotonic biosensors have been positioned as potential solution for the
development of new technologies for SARS-CoV-2 detection and rapid COVID-19 diagnosis [16, 17].
The CONVAT project is one of the first large research projects funded by the H2020 European Union
Framework program (H2020-SC1-PHE-CORONAVIRUS-2020) to fight COVID-19. The main expected
contribution is the early diagnosis and clinical management of patients infected with COVID-19 by
introducing a POC label-free nanophotonic biosensor for the direct, fast and specific identification of
SARS-CoV-2 without requiring complex equipment. CONVAT employs an innovative design of an
evanescent-wave nanophotonic sensor based on silicon photonics interferometric technology, which has
been previously demonstrated for the direct detection of tumor biomarkers and other pathogens with
exceptional sensitivities [18–21]. In this article, we report on the novel COVID-19 diagnostic approaches and
the benefits that POC nanophotonic biosensors may enable, as envisioned in the project, together with the
impact and perspectives for such technology in the boost of global healthcare.
2. Nanophotonic biosensor technology to combat COVID-19: the CONVAT approach
A summary of the CONVAT approach for COVID-19 diagnostics is illustrated in figure 1. The main idea is to
develop an integrated POC biosensor device for accurate detection and identification of the SARS-CoV-2
virus in a few minutes and in decentralized settings. Two diagnostic assays are developed within the same
platform: (a) direct virus detection via antigen recognition, for the rapid infection detection and population
screening; and (b) viral genomic identification via hybridization assay, for diagnostic confirmation.
Additionally, the genomic assay may be multiplexed thereby allowing for rapid discrimination of
different respiratory viruses (e.g. human coronaviruses, influenza, etc) or different coronavirus genera
(i.e. alpha-coronavirus, beta-coronavirus, etc). The latter is particularly interesting for the application of the
CONVAT POC biosensor for environmental screening, that is, for monitoring and characterization of
coronaviruses in reservoir animals, like bats or rodents, which could prevent from future pandemic
outbreaks.
2.1. The bimodal waveguide (BiMW) interferometer
Photonic biosensors are systems that seize different light-based phenomena for the fast detection and
quantification of biomarkers. These devices have become critically important as an efficient tool for
environmental control and clinical health diagnostics. Among the different photonic biosensors, silicon
photonics biosensors based on evanescent-wave sensing principle offer undisputed advantages such as
robustness, reliability, high sensitivity and low power consumption [22]. Principal advantages of this
technology include the small footprint and high scalability of the sensors, made possible via semiconductor
fabrication. These characteristics make this technology ideal for multiplexed analysis, where diagnostic value
improves with increasing panel size. Additionally, the real-time monitoring expedites assay development and
enables rapid direct observation of biological interactions, unlike the endpoint-based detection
methodologies in many standard techniques [23–26].
In the CONVAT project we employ a nanophotonic biosensor based on interferometric bimodal
waveguides (BiMWs) (figure 2). The working principle of a BiMW biosensor is based on the interferometric
design, using a single straight waveguide where light from a coherent source operating at visible wavelengths
is coupled. The BiMW sensor has a first waveguide zone exhibiting single-mode behavior, where only the
fundamental mode is propagating. After some distance, the core thickness of the waveguide is increased and
the light modes are splited in fundamental and first order. Both modes keep travelling through till the output
of the sensor chip. Due to the modes having different velocities and penetrations of their evanescent fields
into the medium, they produce an interference pattern at the exit of the waveguide, which is related to the
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Figure 1. Summary of CONVAT approach for diagnostics and surveillance of COVID-19. A point-of-care biosensor device based
on the bimodal waveguide (BiMW) interferometric technology will be applied for two integrated strategies: the direct detection of
whole intact SARS-CoV-2 viruses for early diagnosis and population screening (left), and for PCR-free viral RNA identification
for both specific diagnosis confirmation and coronavirus surveillance in animal reservoirs (right).
changes induced by any interaction event happening on the sensor surface. This distribution corresponds to
the phase variation of the light between the two modes, which can be measured off the sensor chip with a
sectional photodiode (see figure 2(A)). However, in the BiMW biosensors is important to consider the
existence of a sinusoidal dependence between the phase variation and the wavelength. This problem of the
periodic sensor response and the resulting phase ambiguities, could be solved by modifying the phase
difference between the two propagating modes, altering their effective indices through small variations of the
propagating light wavelength. In that line, we introduced a simple and cost-effective all-optical phase
modulation technique that does not require any additional fabrication processes or external equipment [27].
This configuration provides an excellent sensitivity of detection with a resolution of 10−8 refractive index
units.
The BiMW sensor chip is fabricated using standard silicon microelectronics technology. The design of
the BiMW technology involves waveguides of micro/nanodimensions, which are essential to control the
electromagnetic evanescent field interacting with the molecules in the biorecognition event. Each sensor
consists of a silicon nitride (Si3N4) waveguide covered with a silicon oxide (SiO2) layer used as cladding.
These materials have been selected due to their high refractive index contrast essential for a highly sensitive
transducer based on waveguides. During the process fabrication, a Si3N4 layer (RI 2.00 and 350 nm
thickness) was deposited using low-pressure chemical vapor deposition on a thermally grown SiO2 buffer
layer (RI 1.46, 2 µm thickness). To ensure single-mode behavior in the longitudinal direction in the visible, a
nanometric height rib waveguide (4 µm width× 2 nm height) was formed by buffered HF etching through a
photoresist mask patterned by conventional photolithography. The structure was covered by a SiO2 cladding
layer (RI 1.48 at 633 nm) deposited by plasma-enhanced chemical vapor deposition. Finally, in the bimodal
section, a portion of the cladding is removed defining a sensing area (15× 0.05 mm2) where the evanescent
field of the guided light can probe the surrounding dielectric environment. For the biosensing evaluation, the
BiMW interferometric biosensor is conditioned with a microfluidic flow cell fabricated with an optically
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Figure 2. (A) BiMW biosensor working principle. The inset figure represents the sensing area of the device, where the two
evanescent waves corresponding to the fundamental (yellow) and the first mode (red) of the light are illustrated. (B) Photographs
of the BiMW biosensor chip with 20 independent sensors and its corresponding wafer fabricated with silicon microelectronics
techniques.
transparent polymer (i.e. polydimethylsiloxane, PDMS) for the sample introduction and flowing over the
sensor surface. Each silicon wafer processed contains 12 sensing chips (30× 10 mm2), and each chip includes
an array of 20 BiMW interferometric sensors (figure 2(B)). The simplicity of the design and fabrication of
the BiMW interferometers makes them more attractive for mass production as compared to their
counterparts, the Mach–Zehnder and the Young interferometers.
This robust BiMW biosensor system has been demonstrated previously for the ultrasensitive detection of
clinical biomarkers and pathogens in human fluids for medical diagnostic of infectious diseases. For
example, this biosensor was employed for the detection of several relevant bacteria pathogens, as for the
detection of spontaneous bacterial peritonitis, being capable of detecting Escherichia coli at extremely low
concentrations (Limit of Detection, LOD: 4 CFU ml−1) in human ascitic fluid using a direct immunoassay
[18], with a time to result of only 25 min and with no need of any sample purification. In addition, it was
recently shown the detection of Pseudomonas aeruginosa (LOD ~ 30 CFU ml−1) and methicillin-resistant
Staphylococcus aureus (MRSA), both of them considered as two of the most prevalent bacteria associated with
nosocomial infections. This approach enables the specific identification of the resistant pathogen (MRSA)
and its differentiation from methicillin-susceptible S. aureus [28]. Besides, it was developed an ultrasensitive
methodology for the detection of genes associated with the multidrug-resistance found in Gram-negative
bacteria as E. coli without using PCR amplification. Also, it was applied for the detection of genes encoding
several β-lactamase enzymes able to hydrolyze a broad spectrum of beta-lactams. As a proof-of-concept, the
BiMW biosensor was used to detect two genes of the unamplified genomic DNA directly extracted from
bacteria commonly found in samples of patients attended at the hospital. All the steps took 30 min, achieving
a LOD of only 5.8 aM [29].
2.2. BiMWbiosensor for intact SARS-CoV-2 detection
The possibility to directly detect the presence of viruses in the respiratory tract fluids is a clear sign of early
infection, and if it can be done in a rapid and simple way wherever it is needed, it would allow for massive
screening of the population, enabling efficient identification of infected COVID-19 patients that could be
readily controlled, treated if required, and isolated to stop the disease spread. Furthermore, rather than a
positive/negative response, if the diagnosis can provide information about the viral load, it would drastically
improve the management of patients with a high infection degree, which could be closely monitored for
treatment and assistance to minimize disease complications. This is the main diagnosis strategy proposed in
CONVAT.
In order to capture and detect whole intact viruses from a sample, the BiMW sensor surface is modified
with specific receptors targeting external antigens of the virus, such as the Spike (S) protein of the
SARS-CoV-2 (figure 3(A)). Once the sample is introduced in the biosensor, the virus particles are captured by
the receptors onto the sensor surface, generating an interferometric signal that is recorded in real time. The
sensor response is directly proportional to the concentration of viruses in the sample, therefore providing an
accurate quantification of the viral load in the patient. Two factors are critical for realizing an accurate and
reliable biosensor: the selection of the bioreceptor and its immobilization on the sensor surface. The
selection of the bioreceptors is of paramount importance as they confer the required affinity as well as the
specificity to the assay. Antibodies are the prevailing biorecognition elements used in bioassays development.
These molecules, naturally generated in our body during an immune response, can be produced in vitro in
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large quantities for virtually any type of antigen—namely, proteins, peptides, or small molecules—and they
have demonstrated the greatest affinities and specificities for the targeted antigens. Monoclonal antibodies
are the most widely employed, but several varieties and derivatives can also be produced via genetic
engineering, such as recombinant chimeric antibodies or antibody fragments (i.e. nanobodies), which may
enhance the analytical sensitivity and specificity [30]. On the other hand, aptamers (i.e. oligonucleotide
sequences able to capture and detect specific antigens through structural conformation recognition) have
emerged as possible alternative to antibodies. These bioreceptors offer advantages such as the high stability
and robustness, and the synthetic production and purification at relatively low cost; but, obtaining a
high-affinity and high-selectivity aptamer for certain antigens involves a complex and tedious process that
not always results in the desired features as compared to antibodies [31–33]. Along with the availability and
suitable selection of high-quality bioreceptors, another step that must carefully study and optimize is the
surface biofunctionalization. An optimum biorecognition interface depends on the correct orientation and
density of the bioreceptors, to maximize antigen-recognition efficiency and minimize steric hindrance
effects, and it should also prevent from non-specific binding of other molecules or compounds that might be
present in the sample matrix [34–36]. This is especially relevant since the adsorption of non-specific
components may generate false-positive signals. To achieve so, it is necessary to apply well-controlled surface
chemistry strategies that enable a robust immobilization of bioreceptors and evaluate the assay conditions to
effectively reduce possible background signals while enhancing specific target detection.
Finally, the BiMW biosensor can be applied for the COVID-19 analysis in different patient samples, such
as nasopharyngeal, nasal, or saliva. The presence of virus particles has been confirmed in all these upper
respiratory tract fluids and it represents an opportunity for facilitating the population screening [37].
Although nasopharyngeal swabs are nowadays the preferred option in clinics, it may result disturbing for
some patients, like children, and it requires specialized personnel for appropriate sampling. Nasal fluids or
saliva could be a good alternative for non-invasive sample obtaining and could ideally be performed by the
patients themselves, which would also greatly aid in minimizing the infection risk for sanitary personnel.
Nonetheless and particularly for saliva, it is necessary to evaluate first the large variability of components and
virus levels as well as the different strategies for sample collection. The CONVAT project is foreseen to fulfill
both laboratory and clinical validation of the technology with COVID-positive and negative samples that are
currently being collected in different hospitals around Europe (Italy, France and Spain). Given the
outstanding analytical sensitivity of the BiMW biosensor demonstrated for pathogen detection (below
10 CFU ml−1), the clinical sensitivity is expected to be superior to 95% with 98%–99% specificity, if optimal
bioreceptors are accomplished within the project timeline.
2.3. BiMWbiosensor for viral genomic analysis
Although antigen-based assays can be used for selective screening and detection of COVID-19 infection, the
relatively slight differences in the viral proteins between different virus types may lead to cross-reactivity
issues with the bioreceptors. Also, these proteins are prone to mutate and change structural conformation
very fast, so antibodies might lose affinity or selectivity if they are not re-designed accordingly. Fortunately,
the genomic sequence of a biological entity is unique and exclusive, and some of the regions are usually
conserved for longer times. Therefore, the detection and identification of the viral genomic material (RNA)
leads to the most specific analysis type. In this regard, the CONVAT project envisions such analysis as a
confirmatory diagnostic test, which could be performed in only 30 min as time to result and employing the
same biosensor device. Label-free photonic biosensors can perform specific genomic detection via
hybridization assays without the need of PCR amplification and reaching a comparable sensitivity. In fact,
the BiMW biosensors have demonstrated detection limits in the aM range for direct measurement of RNA
from clinical samples [19, 20]. The assay is simple, and it only requires previous RNA extraction and
fragmentation from the virus, which can be easily done directly upon sample collection. When the sample is
introduced in the biosensor, the specific target gene fragments are captured by complementary
single-stranded DNA probes previously immobilized on the sensor surface, forming a duplex chain, and
leading to real-time signals directly proportional to the number of viruses (figure 3(B)).
To further exploit the capabilities of the nanophotonic BiMW technology, CONVAT aims at developing a
multiplexed genomic biosensor assay. By functionalizing the multiple sensor waveguides with different DNA
probes, we can detect and identify various viruses in the same sample and assay. We could target different
RNA genes of the same SARS-CoV-2—enhancing the selectivity of the assay—or include specific genetic
regions for the identification of other beta-coronaviruses (e.g. SARS-CoV, MERS-CoV) or
alpha-coronaviruses (e.g. hCoVs, responsible for common cold in humans). It could be also possible to
include probes for the detection of influenza viruses and discriminate in one rapid assay whether the patient
suffers COVID-19 or flu, for example. An interesting added value proposed in CONVAT is the utilization of
the POC BiMW genomic biosensor for environmental monitoring, that is, for the analysis and identification
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Figure 3. (A) Illustration of CONVAT strategy for intact SARS-CoV-2 detection with the BiMW biosensor. (B) Illustration of
CONVAT strategy for viral genomic analysis with the BiMW biosensor.
of different coronaviruses in reservoir animals like bats or rodents. The routine control of alpha- or
beta-coronaviruses in animals could greatly help in the early identification of alarming mutated or evolved
viruses, which could eventually infect humans. The availability of a POC biosensor that enables a simple and
rapid screening will simplify the monitoring tasks, deliver timely warnings, and prevent the outbreak of
future pandemics. The project will validate the new BiMW biosensor for both, clinical analysis of human
patient samples collected in different European hospitals and the analysis of bats and rodent feces samples,
which are also being collected in different locations worldwide. Based on previous works proving the
excellent BiMW biosensor sensitivity, the innovative and rapid viral genomic assay is expected to offer
performances comparable to standard PCR-based assays, which are around 98%–100% sensitivity and
specificity.
3. Expected impact
The trend of miniaturization, cost-effectiveness and rapidness of diagnostic devices for an improved and
massive infectious virus screening is undeniably a global public health ambition. A major driver for POC
biosensor development is the ability to diagnose infectious diseases at sites with limited infrastructure
without the requirement to transport the clinical sample to a centralized facility. It is expected that CONVAT
could provide a COVID-19 POC technology as integrated solution for complete, accurate, and reliable virus
analysis.
The outstanding levels of sensitivity demonstrated by the BiMW biosensor anticipate an excellent
performance of the novel POC diagnostic device, with detection limits in the range of 102–103 viruses ml−1
for the direct and rapid SARS-CoV-2 virus screening. Taking into account that common viral loads for
COVID-positive patients are found in the range of 105–107 viruses ml−1, this value is a good indicator that
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the CONVAT technology might be able to diagnose even asymptomatic cases with relatively low viral loads.
Regarding the genomic assay, the ability to directly detect minute concentrations (aM-fM levels) of RNA in
only 30 min in a straightforward manner would greatly increase the accuracy of COVID-19 diagnostics in a
massive population screening. Furthermore, the multiplexing potential could serve in clinics to drastically
reduce the amount of serial analysis needed for disease diagnosis, enabling the direct identification of the
specific infectious virus in less than 1 h.
Finally, it is important to remark the large versatility of the nanophotonic BiMW biosensors. The device
can be considered as a general-purpose instrument to be implemented in hospitals, laboratories, and
primary care centers, and it could be used for routine diagnostic analysis of numerous diseases and medical
conditions. The BiMW sensor chip can be easily adapted for the specific assay of different protein or nucleic
acid biomarkers, and also for the detection and identification of different pathogens, including viruses and
bacteria. The mass production of the chips with conventional silicon microelectronics fabrication techniques
will ensure a low-cost system, which is expected to be below 15 €/assay considering the complete and fully
operative biosensor cartridge, and the on-going advances in system’s connectivity, automation and remote
control, and data analysis and interpretation will be key for realizing that pioneering POC diagnostic
biosensor urgently demanded by the clinics and the society.
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